Caseware UK (AP4) 2024.0.164 2024.0.164 2025-10-312025-10-31falseNo description of principal activity282024-11-0123falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 05221407 2024-11-01 2025-10-31 05221407 2023-11-01 2024-10-31 05221407 2025-10-31 05221407 2024-10-31 05221407 2023-11-01 05221407 c:Director1 2024-11-01 2025-10-31 05221407 d:Buildings 2024-11-01 2025-10-31 05221407 d:Buildings 2025-10-31 05221407 d:Buildings 2024-10-31 05221407 d:Buildings d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 05221407 d:MotorVehicles 2024-11-01 2025-10-31 05221407 d:MotorVehicles 2025-10-31 05221407 d:MotorVehicles 2024-10-31 05221407 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 05221407 d:FurnitureFittings 2024-11-01 2025-10-31 05221407 d:FurnitureFittings 2025-10-31 05221407 d:FurnitureFittings 2024-10-31 05221407 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 05221407 d:OfficeEquipment 2024-11-01 2025-10-31 05221407 d:OfficeEquipment 2025-10-31 05221407 d:OfficeEquipment 2024-10-31 05221407 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 05221407 d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 05221407 d:CurrentFinancialInstruments 2025-10-31 05221407 d:CurrentFinancialInstruments 2024-10-31 05221407 d:Non-currentFinancialInstruments 2025-10-31 05221407 d:Non-currentFinancialInstruments 2024-10-31 05221407 d:CurrentFinancialInstruments d:WithinOneYear 2025-10-31 05221407 d:CurrentFinancialInstruments d:WithinOneYear 2024-10-31 05221407 d:Non-currentFinancialInstruments d:AfterOneYear 2025-10-31 05221407 d:Non-currentFinancialInstruments d:AfterOneYear 2024-10-31 05221407 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-10-31 05221407 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-10-31 05221407 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-10-31 05221407 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-10-31 05221407 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2025-10-31 05221407 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2024-10-31 05221407 d:ShareCapital 2025-10-31 05221407 d:ShareCapital 2024-10-31 05221407 d:ShareCapital 2023-11-01 05221407 d:RetainedEarningsAccumulatedLosses 2024-11-01 2025-10-31 05221407 d:RetainedEarningsAccumulatedLosses 2025-10-31 05221407 d:RetainedEarningsAccumulatedLosses 2023-11-01 2024-10-31 05221407 d:RetainedEarningsAccumulatedLosses 2024-10-31 05221407 d:RetainedEarningsAccumulatedLosses 2023-11-01 05221407 c:FRS102 2024-11-01 2025-10-31 05221407 c:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 05221407 c:FullAccounts 2024-11-01 2025-10-31 05221407 c:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 05221407 2 2024-11-01 2025-10-31 05221407 e:PoundSterling 2024-11-01 2025-10-31 iso4217:GBP xbrli:pure

Registered number: 05221407









IMEDICARE LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 OCTOBER 2025

 
IMEDICARE LIMITED
REGISTERED NUMBER: 05221407

BALANCE SHEET
AS AT 31 OCTOBER 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 5 
414,429
408,800

Current assets
  

Stocks
 6 
1,344,747
1,335,118

Debtors: amounts falling due within one year
 7 
828,600
770,949

Cash at bank and in hand
 8 
488,885
480,608

  
2,662,232
2,586,675

Creditors: amounts falling due within one year
 9 
(876,159)
(1,103,500)

Net current assets
  
1,786,073
1,483,175

Total assets less current liabilities
  
2,200,502
1,891,975

Creditors: amounts falling due after more than one year
 10 
(40,070)
(66,435)

Net assets
  
2,160,432
1,825,540


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
2,160,332
1,825,440

  
2,160,432
1,825,540


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.
 

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 22 June 2026.


................................................
Darren Breen
Director

Page 1

 
IMEDICARE LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2025


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 November 2023
100
1,374,000
1,374,100


Comprehensive income for the year

Profit for the year
-
731,190
731,190

Dividends: Equity capital
-
(279,750)
(279,750)



At 1 November 2024
100
1,825,440
1,825,540


Comprehensive income for the year

Profit for the year
-
671,892
671,892

Dividends: Equity capital
-
(337,000)
(337,000)


At 31 October 2025
100
2,160,332
2,160,432


The notes on pages 3 to 10 form part of these financial statements.

Page 2

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

1.


General information

Imedicare Limited is a private company limited by share capital, incorporated in England and Wales, registration number 05221407. The address of the registered office is 27 Rosemary Drive, Napsbury Park, London Colney, Herts, AL2 1UD.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on a going concern basis as the director believe  adequate resources exist to enable it to meet its working capital requirements for at least twelve months from approval of these financial statements.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Page 3

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.Accounting policies (continued)

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.7

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.Accounting policies (continued)

 
2.9

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Freehold property
-
No Depreciation
Motor vehicles
-
25%
Reducing balance
Fixtures and fittings
-
25%
Straight Line
Office equipment
-
25%
Straight Line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.11

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.12

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 5

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.Accounting policies (continued)

 
2.13

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.14

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.15

Financial instruments

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.




 
Page 6

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.Accounting policies (continued)


2.15
Financial instruments (continued)

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Employees

The average monthly number of employees, including directors, during the year was 28 (2024 - 23).


4.


Dividends

2025
2024
£
£

Ordinary


Dividends
337,000
279,750

337,000
279,750

Page 7

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

5.


Tangible fixed assets





Freehold property
Motor vehicles
Fixtures and fittings
Office equipment
Total

£
£
£
£
£



Cost or valuation


At 1 November 2024
301,251
276,497
10,661
19,485
607,894


Additions
-
35,142
1,428
7,725
44,295


Disposals
-
(16,990)
-
-
(16,990)



At 31 October 2025

301,251
294,649
12,089
27,210
635,199



Depreciation


At 1 November 2024
-
178,692
7,975
12,427
199,094


Charge for the year on owned assets
-
32,938
1,029
3,691
37,658


Disposals
-
(15,982)
-
-
(15,982)



At 31 October 2025

-
195,648
9,004
16,118
220,770



Net book value



At 31 October 2025
301,251
99,001
3,085
11,092
414,429



At 31 October 2024
301,251
97,805
2,686
7,058
408,800


6.


Stocks

2025
2024
£
£

Finished goods and goods for resale
1,344,747
1,335,118

1,344,747
1,335,118


Page 8

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

7.


Debtors

2025
2024
£
£


Trade debtors
756,109
719,766

Other debtors
22,388
20,476

Prepayments and accrued income
50,103
30,707

828,600
770,949



8.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
488,885
480,608

488,885
480,608



9.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank loans
12,048
18,572

Other loans
6,000
6,000

Trade creditors
418,315
558,337

Corporation tax
231,370
257,611

Other taxation and social security
178,232
177,697

Obligations under finance lease and hire purchase contracts
19,410
392

Other creditors
1,890
76,114

Accruals and deferred income
8,894
8,777

876,159
1,103,500


Page 9

 
IMEDICARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

10.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
37,570
57,935

Other loans
2,500
8,500

40,070
66,435



11.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Bank loans
12,048
18,572

Other loans
6,000
6,000


18,048
24,572

Amounts falling due 1-2 years

Bank loans
12,048
18,572

Other loans
2,500
6,000


14,548
24,572

Amounts falling due 2-5 years

Bank loans
24,096
37,143

Other loans
-
2,500

24,096
39,643

Bank loans
1,426
2,220

58,118
91,007


The company has aggregate loans at 31 October 2025 of £58,118 (2024: £91,007). 
The company has the following loans: a mortgage loan which has a variable interest rate of 4.42% plus the Bank of England base rate, and a Bounce Back Loan which has an interest rate of 2.5%. All are repayable by monthly installments.

 
Page 10